See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/23305675
Matrix Gla-protein: The calcification inhibitor
in need of vitamin K
ARTICLE in THROMBOSIS AND HAEMOSTASIS · NOVEMBER 2008
Impact Factor: 4.98 · DOI: 10.1160/TH08-02-0087 · Source: PubMed
CITATIONS
READS
107
145
3 AUTHORS:
Leon J Schurgers
Ellen C M Cranenburg
174 PUBLICATIONS 5,811 CITATIONS
16 PUBLICATIONS 797 CITATIONS
Maastricht University
SEE PROFILE
Maastricht Universitair Medisch Centrum
SEE PROFILE
Cees Vermeer
Maastricht University
313 PUBLICATIONS 8,304 CITATIONS
SEE PROFILE
Available from: Leon J Schurgers
Retrieved on: 03 February 2016
Theme Issue Article
Matrix Gla-protein: The calcification inhibitor in need of vitamin K
Leon J. Schurgers, Ellen C. M. Cranenburg, Cees Vermeer
VitaK and Cardiovascular Research Institute (CARIM), Maastricht University, Maastricht, The Netherlands
Summary
Among the proteins involved in vascular calcium metabolism,
the vitamin K-dependent matrix Gla-protein (MGP) plays a
dominant role.Although on a molecular level its mechanism of
action is not completely understood,it is generally accepted that
MGP is a potent inhibitor of arterial calcification. Its pivotal importance for vascular health is demonstrated by the fact that
there seems to be no effective alternative mechanism for calcification inhibition in the vasculature.An optimal vitamin K intake
is therefore important to maintain the risk and rate of calcification as low as possible.With the aid of conformation-specific
Keywords
Matrix Gla-protein, vitamin K, calcification, cardiovascular disease, oral anticoagulants
Background
Matrix Gla-protein (MGP) is a small secretory protein that can
undergo two types of posttranslational modification: γ-glutamate carboxylation and serine phosphorylation. The protein was
first described in 1983 by Price et al. who purified it from the
bovine bone matrix (1). The authors concluded that this approximately 14 kD protein contains five unusual amino-acids designated as γ-carboxyglutamate (abbreviated as Gla), and therefore
the protein was designated as matrix Gla-protein (Fig. 1). Soon
after its discovery in bone, MGP synthesis in cartilage, lung,
heart, kidney, arteries and calcified atherosclerotic plaques was
confirmed (1–3). The mature protein consists of 84 amino-acids
and has a theoretical PI of 9.7. Of the nine glutamate residues
only five can be γ-carboxylated in a vitamin K-dependent reaction, and three of its five serine residues can be phosphorylated
into phosphoserine (abbreviated as Pser). The MGP gene is located on chromosome 12 (p13.1-p12.3), consists of four exons
and three large introns and has a length of 3.9 kb. It contains
metal responsive elements and presents putative binding sites for
AP1 and AP2 and cAMP-dependent transcription factors. At
physiological levels, vitamin D3 increased MGP transcription in
VSMC whereas retinoic acid down regulates its expression (4).
antibodies MGP species in both tissue and the circulation have
been detected in the healthy population, and significant differences were found in patients with cardiovascular disease (CVD).
Using ELISA-based assays, uncarboxylated MGP (ucMGP) was
demonstrated to be a promising biomarker for cardiovascular
calcification detection.These assays may have potential value for
identifying patients as well as apparently healthy subjects at high
risk for CVD and/or cardiovascular calcification and for monitoring the treatment of CVD and vascular calcification.
Thromb Haemost 2008; 100: 593–603
The best studied posttranslational modulation of MGP is
gamma-glutamate carboxylation. Gla-residues are formed in a
unique posttranslational modification carried out by the enzyme
gamma-glutamate carboxylase (5). The only unequivocal role of
vitamin K is to provide the energy to drive the carboxylase reaction. The Gla-residues formed are negatively charged and proteins in which they are found are denominated as Gla-proteins. A
common characteristic of all known members of this protein
family is that the Gla-residues are absolutely required for protein
activity (6). In all Gla-proteins the affinity for gamma-glutamate
carboxylase is determined by a pro-sequence located immediately at the N-terminal site of the protein. In most Gla-proteins
the pro-sequence is cleaved off during maturation; MGP is the
exception in this respect, since the mature protein contains an internal pro-peptide which may contribute to its unique properties.
Phosphorylation, the other posttranslational modification in
MGP, may take place at serine residues in positions 3, 6 and 9
(Fig. 1). Price et al. showed that the motif in MGP recognized for
serine phosphorylation is the tandemly repeated Ser-X-Glu sequence (4). Phosphorylation is carried out by the Golgi casein kinase (4, 7). The function of serine phosphorylation is not precisely known, but recent data suggest that it plays a role in regulating the secretion of proteins into the extracellular environ-
Received February 14, 2008
Accepted after minor revision July 2, 2008
Correspondence to:
Dr. L. J. Schurgers
VitaK, Maastricht University
Universiteitssingel 50
6200 MD Maastricht, The Netherlands
Tel.: +31 43 3881680, Fax: + 31 43 388 4159
E-mail: l.schurgers@bioch.unimaas.nl
Prepublished online September 5, 2008
doi:10.1160/TH08-02-0087
593
New vitamin K-dependent proteins
© 2008 Schattauer GmbH, Stuttgart
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
Figure 1: Matrix Gla-protein (MGP) is a small 84aa
vitamin K-dependent protein. Although its 14 kD size,
it can undergo two posttranslation modifications: at position 3, 6, and 9 the serine residues can be phosphorylated by
a Golgi-casein kinase, and at
positions 2, 37, 41, 47 and 52
the glutamate residues can be
γ-carboxylated (117).
ment. Wajih et al. showed that phosphorylated MGP exits vascular smooth muscle cells (VSMCs) via the secretory pathway,
whereas the non-phosphorylated MGP appears in the cytosol,
and is thus not secreted (7).
The fat-soluble vitamins A and D may modulate MGP expression. Retinoic acid is a regulator of chondrocyte maturation
and mineralization (8). Its effect on mRNA expression levels of
MGP is cell type-dependent: in fibroblasts, chondrocytes, osteoblasts, and type II pneumocytes, retinoic acid upregulates
MGP mRNA expression (9, 10) whereas in kidney cells and
VSMCs, retinoic acid downregulates MGP expression (11, 12).
1,25(OH)D3 was shown to increase MGP expression in vitro in
VSMCs (11). In models in vitro (13), animal models (14) and humans (15), extremely high vitamin D intakes may cause vascular
calcification, most likely due to an effect on calcium-metabolism.
Functions of MGP
Although the precise molecular mechanisms of MGP function
are not known, accumulating data demonstrate its major role in
the inhibition of soft-tissue calcification. The first clues for a
Gla-protein being involved in the inhibition of tissue calcification came from rats treated with the vitamin K-antagonist warfarin (16). These animals developed massive cartilage calcification, notably in the epiphyses and facial bones, leading to impaired growth, maxillonasal hypoplasia and reduction in the
length of the nasal bones (17). It was only after the identification
of MGP in cartilage that it was recognized that the cartilage calcification was brought about by loss of MGP function (18). After
its discovery, it was thought for many years that the importance
of MGP was restricted to bone and cartilage metabolism. By targeted deletion of the MGP gene in mice it became clear, however,
that its main function is the inhibition of medial calcification of
the arteries: MGP-deficient animals all died within six to eight
weeks after birth due to calcification of the elastic lamellae in the
tunica media, resulting in rupture of the large arteries (19). The
arterial calcification in the MGP null mice resulted from the precipitation of calcium-phosphate in a ratio similar to hydroxyapatite, thus mimicking bone mineralisation. Using histochemical
techniques, the authors demonstrated that the arterial calcification was associated with the differentiation of VSMCs into
chondrocyte-like cells. A mechanism explaining the strong calcification inhibitory activity of MGP was put forward by Price,
who suggested that MGP binds tightly to the crystal nuclei thus
preventing further growth (20). Inhibition of the differentiation
of VSMCs into chondocyte- and osteoblast-like cells may be a
second function of MGP for which further support was provided
in MGP-deficient mice by demonstrating a loss of smooth
muscle markers and upregulated expression of the bone-specific
transcription factor cbf1a/Runx2 and the osteogenic protein osteopontin (21). The ability of MGP to keep VSMCs in the contractile phenotype may be accomplished by binding to the bone
morphogenetic protein-2 (BMP-2) (22, 23). BMP-2 is a member
of the transforming growth factor-beta (TGF-beta) superfamily,
and is an osteogenic growth factor. BMP-2 has been shown to be
expressed in human atherosclerotic lesions (24). Wallin et al.
demonstrated that only the carboxylated form of MGP binds to
BMP-2 (22); moreover, Bostrom et al. presented data suggesting
that MGP blocks the osteo-inductive properties of BMP-2 (25).
This inhibitory function is further supported by work of Shanahan et al., who showed that MGP expression is lower in the media
of arteries from diabetic patients with Mönckeberg's sclerosis
than in normal vessels (26). Via its C-terminal region, MGP can
also bind to the extra-cellular glycoprotein vitronectin, which is
present in the extra cellular matrix of the arteries (27). The C-terminal part of MGP is hydrophobic and does not contain Gla- or
Pser-residues, which are all present in the more hydrophilic
594
N-terminal and mid-section of the molecule. It may be hypothesized that MGP’s binding to vitronectin results in a concentration
of calcification-inhibitory activity in the milieu surrounding the
elastic fibers, thereby protecting them from mineralization.
Formation of matrix vesicles (MV) and apoptotic bodies
(AB) is thought to precede and/or initiate arterial calcification.
VCSMs undergoing apoptosis provide negatively charged membrane particles which – if not phagocytosed properly – play a role
in the initiation of calcification (28). The physiological function
of these extracellular membrane particles is to serve as the initial
nidus of calcification in cartilage. Also in the vessel wall, both
MV and AB are relatively common, notably in atherosclerotic
plaques (29, 30), arterial injury (31) and Mönckeberg's sclerosis
(32, 33). When VSMCs are grown in culture they can form multicellular nodules, containing a high number of AB. MGP expression is highest in this phase, suggesting an association between MGP and apoptosis. Reynolds et al. showed in cell culture
systems that VSMC derived MV and AB both contained MGP
which is thought to limit the rate of calcification (34).
The specific knock-in expression of MGP in VSMCs of
MGP-deficient mice completely rescued the calcification phenotype (35). In the same article the authors also expressed MGP
in the liver of MGP-deficient mice, resulting in high levels of
circulating MGP. However, the elevated systemic levels of MGP
had no effect on inhibition of arterial calcification implying that
MGP inhibits calcification by acting locally within its tissue of
synthesis, not systemically. In humans, mutations in the gene encoding for MGP – predicting a non-functional protein – cause
the Keutel syndrome (36), a rare disorder characterized by abnormal cartilage calcification and peripheral pulmonary stenosis (37). Post mortem examination of a young Keutel patient also
revealed extensive arterial calcification (38).
Arterial calcification
Until a decade ago, calcification of arteries was thought to be a
passive, clinically irrelevant process, resulting from a high calcium x phosphate product, inflammation, lipid accumulation or
diabetes. However, during recent years it has become increasingly clear that vascular calcification is an active process and an
important, independent pathology that is strongly associated
with increased risk of cardiovascular morbidity and mortality
(39–41). Clinically, vascular calcification causes stiffening of
the vascular wall, which may result in decreased arterial compliance, development of left ventricular hypertrophy and decreased coronary perfusion leading to an increased risk of fatal
complications (42, 43). Calcification is common in the elderly
population, and in patients suffering from diseases such as
chronic kidney disease (CKD), diabetes, aortic stenosis, and
atherosclerosis (44). Therefore, a lot of efforts have been directed towards retarding or reversing the development of calcification in the vasculature. In animal models it has been shown that
arterial calcification is reversible (45–48), demonstrating that
also the regression process is an actively regulated process. In
humans, attempts to use lipid lowering drugs (statins) to stabilize
or regress calcification have so far failed to show a significant effect (49, 50).
CKD patients have the highest incidence of arterial calcification, and cardiovascular mortality is 20-fold higher than in the
apparently healthy population (51, 52). Moreover, moderate to
severe vascular calcifications are found in 60–80% of patients on
hemodialysis (53, 54). Recently, it was shown that vitamin
K-status in CKD patients is low (55). Circulating vitamin K levels were measured and reported that some 30% of the haemodialysis patients had sub-clinical vitamin K-deficiency. The authors discussed the possibility of giving these patients extra vitamin K to reduce the risk for cardiovascular events (55). Additionally, the need for vitamin K in patients might be much higher
than in the general population. Anticoagulation therapy with vitamin K antagonists, which is regularly prescribed in these patients, will exacerbate the low vitamin K-status in these patients.
Together with the additional immunohistochemical evidence of
high levels of uncarboxylated MGP (ucMGP) present in calcified areas (47, 56, 57), these data are suggestive for high vitamin
K intake as a novel treatment option for cardiovascular calcification (see also below). The first clinical studies in dialysis patients are in progress.
Factors affecting MGP activity
Vitamin K / warfarin
It has been known for a long time that women receiving anticoagulant therapy with vitamin K antagonists (coumarin derivatives) during the first trimester of pregnancy are at risk of delivering children with a syndrome characterized by nasal hypoplasia, depression of the nasal bridge and punctuate calcifications in the axial skeleton, proximal femurs and calcanei (58).
This syndrome is known as warfarin embryopathy (fetal warfarin
syndrome), and the abnormalities were first believed to be
caused by haemorrhages in the developing fetal cartilages with
subsequent calcification of these areas (58–60). However, it was
soon recognized that this was unlikely, since clotting factors
were known to be absent during the first trimester of pregnancy
(58, 61). Similarities between the facial and skeletal abnormalities seen in warfarin embryopathy and the fetal phenytoin (hydantoin) syndrome suggested that prenatal vitamin K-deficiency
may underlie these abnormalities (58, 62). This was confirmed
by Pauli et al. who described a congenital deficiency of the
enzyme vitamin K-epoxide reductase (VKOR, needed for recycling of vitamin K), causing prenatal vitamin K deficiency, and
resulting in a similar phenotype (63, 64). In later years it was reported that also dietary vitamin K-deficiency results in comparable calcification abnormalities (65–69), which were remarkably similar to the bone and cartilage defects observed in warfarin-treated rats (16). The same animal model provided the first
evidence that impairment of MGP function results in vascular
calcification (20). It was found that within two weeks of warfarin treatment, the elastin fibres in the tunica media were significantly calcified. Further evidence for the pivotal role of Gla residues for MGP function was provided by Murshed et al. who used
the MGP null mice in which MGP cannot be carboxylated, since
the glutamate residues in the Gla-domain were mutated into aspartate; in this way it was demonstrated that only carboxylated
MGP (cMGP) exhibits anti-mineralization properties (35). Vitamin K antagonists are frequently used to prevent thrombosis in
595
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
patients at increased risk for thrombosis (70). Treatment periods
range from several weeks to many years, even often life-long
(71). After demonstration in animal models that vitamin K antagonists induce vascular calcification, studies in two independent populations revealed that indeed treatment with coumarin
derivatives induces excessive calcification of the coronary arteries and the aortic heart valve (72, 73). Schurgers et al. compared valvular calcification in patients receiving oral anticoagulant treatment for a period of between 16 and 35 months with patients not on oral anticoagulation (72). Histopathological evaluation of the valves from the patients who had received oral anticoagulation showed partial or total valve destruction induced by
amorphous calcified deposits. Quantification of the calcium
contents of the aortic valves showed a statistically significant
difference between valves from those who had never received
oral anticoagulant treatment and those who had received this
treatment. These data were confirmed by Koos et al., who used
multislice spiral computed tomography (CT) to quantitate the
extent of aortic calcification in patients on long term oral anticoagulant treatment (73). It was found that these patients had increased coronary calcification compared to patients without
anticoagulation treatment (Agatston score 1,561 and 738, respectively). The present policy is opposite, however: large
numbers of cardiovascular disease (CVD) patients receive anticoagulant therapy with vitamin K antagonists, which increases
their calcification tendency. The data described above suggest
that – if possible – other forms of anticoagulation (specific prothrombin or factor-X inhibitors) should be employed, preferably
in combination with high vitamin K intake. This treatment could
activate MGP, and the intriguing question remains whether it decreases CVD in parallel. Together, these data demonstrate a hitherto unrecognized adverse side-effect of coumarin derivatives
which should be considered when designing optimal anti-thrombotic treatments for patients.
Vitamin K comprises a family including vitamin K1 (phylloquinone) and vitamin K2 (menaquinones). The mechanism of
vitamin K1 is believed to be most important for activation of hepatic clotting factors whereas K2 also is important for proteins
synthesized in extra-hepatic tissues such as the vasculature.
Moreover, there is now scientific evidence that K2 vitamins have
additional properties, including apoptosis and cell-cycle arrest
and anticancer properties (74, 75), inhibition of the synthesis of
prostaglandin E2 (PGE2) (76), osteoclast apoptosis (77), and
binding to the SXR in the osteoblast, resulting in induction of osteoblastic markers (78). Recently, it was shown that vitamin K2
could also down regulate osteoprotegrin and increase DT-diaphorase, implicating that vitamin K2 is an anti-calcification
component in the vessel wall (79). For a more extensive review
on the gene regulatory functions of vitamin K2, see Shearer article, this volume beginning on page 530.
The question of whether high vitamin K-intake is protective
against arterial calcification was first addressed in a populationbased study among participants of the Rotterdam Study. It was
demonstrated that dietary vitamin K2 intake (and not K1) was inversely correlated with cardiovascular calcification and cardiovascular death (6). Elderly people in the highest tertile of vitamin
K2 intake had about 50% reduction in both aortic calcification
and cardiovascular mortality and 25% decreased all-cause mor-
tality. In a clinical intervention study in which 78 women between 55 and 65 years of age received either vitamin K (1 mg/
day) or placebo for three years, vascular characteristics were assessed (elasticity and distensibility) (80). In subjects in the
placebo group vascular elasticity had decreased by 10–13%,
which is consistent with the normal decrease during the timeperiod of three years; in the vitamin K group, however, vascular
characteristics had remained unchanged, suggesting that the process of vascular aging can be retarded by increased vitamin K intake.
The concept of calcification inhibition by high vitamin K intake was confirmed in experimental animals (81). In this model
the efficacy of vitamins K1 and K2 in preventing arterial calcification was compared. It was found that K2 completely inhibited
tissue calcification, whereas a similar or even an eight-fold
higher dose of K1 had no measurable effect. To fully understand
this model it is important to know that vitamin K1 can be converted into MK-4 via MK4-O, but that warfarin blocks the conversion of MK4-O into reduced MK4, which is the active cofactor (82). Buitenhuis et al. showed that K2 vitamins, especially the
long chain K2 vitamins such as menaquinone-7, have lower KM
values for the enzyme γ-glutamyl carboxylase, demonstrating
that they are the preferred cofactor for vascular carboxylase (83).
Additionally, recently Wallin et al. showed that specifically K2
acts as an anti-calcification component in the vessel wall by increasing the gene expression with a 4.8-fold higher specific activity of DT-diaphorase, an enzyme of the vitamin K-cycle (79).
The same animal model was used to study the effect of high vitamin K intake on potential regression of arterial calcification
(47). Whereas rats receiving the standard chow (control) had
very low aortic calcium during the entire experiment, a six-week
warfarin treatment led to the accrual of calcium salts up to
12-fold above the baseline values. During the following sixweek period warfarin treatment was stopped and the animals received either standard chow or standard food fortified with a
high dose of vitamin K1 or K2. It was shown that once calcium
deposits had formed, the accrual of calcium salts in the vasculature increased linearly after the warfarin diet had been replaced
by the normal dose of vitamin K. At high doses of either K1 or K2,
however, the process of calcification was not only stopped, but a
significant fraction (some 40%) of the previously formed calcium salts had been removed within six weeks. This effect was
found both in the aorta and in the coronary arteries. Using immunohistochemistry it was demonstrated that parallel to the regression of aortic calcium content, cMGP had increased and ucMGP
had decreased, suggesting a role of activated MGP in the regression of calcified plaques. The fact that vitamins K1 and K2 had a
similar effect in this experiment may be explained by the very
high dosages used, and by the fact that in the absence of warfarin
up to 25% of the vitamin K1 may be converted into K2 (84). Only
by performing dose-response studies the efficacies of both vitamins may be compared in this model.
Carboxylase / VKOR
Mutations in the γ-glutamate carboxylase gene result in bleeding
disorders due to the inability to activate sufficient vitamin K-dependent clotting proteins (85, 86). Since only one gene encodes
for the enzyme, also Gla-proteins produced in extra-hepatic tis-
596
sues are affected by this mutation. More recently it was shown
that patients with the γ-glutamate carboxylase mutation not only
presented with haemostatic disorders, but also with soft tissue
calcifications, as is seen in patients with a pseudoxanthoma elasticum (PXE)-like phenotype (87). Pseudoxanthoma elasticum is
an autosomal recessive multi-system disorder characterized by
dystrophic mineralization of soft tissues, including skin, eyes,
and arterial blood vessels (88). Whereas classic PXE is caused by
mutations in the ABCC6 gene (ATP-binding cassette subfamily
C member 6), patients with the PXE-like syndrome harboured
known γ-glutamate carboxylase mutations in six out of seven patients analyzed. The involvement of MGP in classic PXE was recently demonstrated by two groups, showing that fibroblasts
from PXE patients almost exclusively produce the inactive
ucMGP, which is not able to block or inhibit calcification (89,
90). The very low cMGP production in pathological fibroblasts
compared to controls suggests these cells have a deficient vitamin K metabolism which may play an important role in the ectopic calcification in PXE.
The vitamin K-epoxide reductase (VKOR) enzyme is a crucial enzyme in vitamin K metabolism and ensures the re-utilization of vitamin K after it has been oxidized in the carboxylase
reaction. Because of this recycling, human vitamin K requirement is extremely low (91). On a molecular level VKOR reduces
vitamin K-epoxide in two steps: first to the quinone, and subsequently to vitamin K hydroquinone (KH2), which is the active cofactor for γ-glutamate carboxylase. VKOR is also the target for
warfarin and related coumarin derivatives, which block the recycling of vitamin K thereby decreasing the vitamin K-status.
Both vitamin K-epoxide and vitamin K quinone need to bind to
the VKOR before being reduced. Wallin et al. showed that the
enzyme DT-diaphorase in VSMCs is 100-fold less active than in
the liver. The cytoplasmic DT-diaphorase is capable of reducing
vitamin K quinones to their hydroquinone cofactors, and serves
as a rescue enzyme in case the VKOR is blocked by coumarin
(92, 93). Therefore, coumarin treatment has a detrimental effect
in the arterial vessel wall, by blocking vitamin K-metabolism
leading to impaired MGP. Moreover, the vitamin K binding site
in VKOR is thought to be close to the coumarin-binding site and
recently it was shown that the presence of various VKORC1 haplotypes correlates with arterial vascular disease (94).
Besides being a cofactor in the vitamin K-dependent carboxylation, KH2 also possesses antioxidant activity (95, 96).
This is consistent with its high sensitivity to free radicals, which
may oxidize (and thus inactivate) KH2 before it can take part in
the carboxylation reaction. Especially in the atherosclerotic
plaque, high levels of oxidized LDL are found, which may thus
contribute to a local vitamin K deficiency.
MGP as biomarker
As discussed above, MGP is one of the strongest inhibitors of arterial calcification, its function depending on the presence of vitamin K. MGP is a local inhibitor of vascular calcification and it
has been demonstrated that circulating MGP has no biological
function (35). However, circulating MGP may reflect calcification processes and inhibition of those processes in the vascular
wall. Below we will discuss the presence of MGP in vascular tis-
Table 1: Matrix Gla-protein antibodies. moAb = monoclonal
antibody; W = Western blot; I = immunoprecipitation; S = section;
E = ELISA. Antibodies available at VitaK Products BV (www.vitak.org)
Aminoacid
Specificity
Used
Directed against
moAb dpMGP
3–15
IgG1a
W, I, S, E
Desphosphorylated MGP
moAb pMGP
3–15
IgG1a
W, I, S, E
Phosphorylated MGP
moAb ucMGP
35–54
IgG1a
W, I, S, E
Uncarboxylated MGP
moAb cMGP
35–54
IgG1a
W, I, S, E
Carboxylated MGP
Table 2: Possibilities of MGP ELISA’s. Four single antibody competitive assays can be developed, namely dpMGP, pMGP, ucMGP and
cMGP conformation. Also, antibodies directed against the C-terminal
part of MGP could be used to measure the total of MGP proteins. These
monoclonal antibodies are not available yet. Combinations of the conformation specific antibodies could result in several MGP sandwich combinations. Here we hypothesise that dp-ucMGP is the inactive fraction
whereas p-cMGP represents the active MGP fraction. More research is
needed to find out the exact role of the different MGP combinations.
Phosphorylation dpMGP
Carboxylation
ucMGP
cMGP
pMGP
inactive MGP fraction
active MGP fraction
sue and in the circulation, and the potential of circulating MGP
as a biomarker for cardiovascular calcification.
MGP in vascular tissue
Immunohistochemical studies have shown that in healthy vessels
MGP is synthesized at relatively low rate (2, 57, 97), most likely
because the need for calcification inhibition is low. However,
Shanahan et al. showed that in arteries of diabetic patients lower
levels of MGP protein were present than in normal vessels, suggesting that low MGP levels might predispose for calcification
(26). High MGP levels have been detected in arteries with calcification (2, 57, 97). This may originate from increased MGP
synthesis, which has been reported in both medial and intimal arterial calcification (2, 57, 97), or increased subsequent adsorption to the calcium salt crystals.
With the development of conformation-specific antibodies,
enabling the detection of active, carboxylated and inactive, uncarboxylated MGP (cMGP and ucMGP, respectively), it became
clear that specifically the ucMGP conformation accumulates in
atherosclerotic and calcified arteries (56, 57, 90). The cMGP
conformation was nearly absent in these arteries. These conformation-specific antibodies have proven their value for MGP
detection and studying vitamin K-metabolism in several animal
models. Wajih et al. demonstrated the processing and transport
of the different MGP conformations in cultured VSMCs (7). In
this article the complexity of MGP processing and excretion was
clearly presented by using conformation specific antibodies
against MGP. Sweatt et al. demonstrated that calcified arterial
lesions in aging rats contained elevated MGP levels, which was
uncarboxylated and not able to bind BMP-2 (56). Our group
demonstrated massive accumulation of ucMGP around calcified
597
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
Figure 2: Vitamin K-dependent regulation of vascular calcification. A) Vitamin K-sufficiency: In the case of sufficient vitamin K
supply (either via food or supplements) and in the absence of disease, all
MGP synthesised in the VSMCs is activated to prevent calcification: the
clearance of matrix vesicles (MV) and apoptotic bodies (AB) is supported by either macrophages and/or surrounding VSMCs. In this way,
the nidus for calcification is absent. There is no hydroxyapatite matrix in
the tunica media to bind to MGP. The fraction of MGP leaking into circulation is the dp-cMGP and p-cMGP. B) Vitamin K-insufficiency: Vitamin K
insufficiency is present in subjects with sustained low vitamin K intake or
patients on vitamin K-antagonist (coumarin derivatives). The expression
of MGP is normal. The inactive MGP will lead to decreased clearance of
MV and AB. The negatively charged phospholipid-remnants have the capacity to nucleate calcium and phosphate and subsequently calcify in the
absence of the calcification inhibitory function of MGP. The phosphorylated ucMGP fraction will bind to the vascular calcification, and thus the
p-ucMGP is lowered. The fraction easily released in the circulation is dpucMGP (this fraction has no or limited affinity for vascular calcium). Vitamin K-insufficiency (as deduced from inactive ucMGP species in the circulation) is present in the majority of the apparently healthy population.
C) Calcification triggered by disease: In diseases leading to the shedding
of high numbers of MV and AB, calcification is triggered and the need for
598
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
active MGP is high. Also in diseases with a balance in favour of calcification, e.g. high calcium-phosphate product (ESRD), inflammation (leading to apoptosis), a high synthesis of MGP is needed to counteract the
nidus for calcification. In response, the demand for vitamin K increases.
In the majority of the population the intake of vitamin K is insufficient to
address this higher demand of vitamin K, required for the activation of
all newly synthesised MGP. Therefore, a major part will occur in the
ucMGP conformation, unable to stop or reverse calcification; MGP will
bind to the local vascular calcifications via the p-ucMGP conformation
which will be measured by the lower plasma p-ucMGP levels. The circu-
lating MGP fraction which has no or limited affinity of calcium (dpucMGP) is high in this situation. D) High vitamin K-intake: Once calcifications are present, and dp-ucMGP is high, high intake of vitamin K
could be used as treatment option. In this way, all newly synthesised
MGP will be activated via the γ-carboxylation reaction. This will result in
dp-cMGP and p-cMGP. As the active MGP fraction will support clearance
/ regression of calcification the amount of calcification will reduce. In the
circulation, this will be reflected by a lowered dp-ucMGP level, demonstrating a beneficial shift in the tissue.
599
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
lesions which are rapidly formed in the arteries of rats during
treatment with warfarin. Additionally, it appeared that high vitamin K intake resulted in improved MGP carboxylation, regression of pre-formed calcifications and subsequent increased vascular elasticity (47). The conformation-specific antibodies have
recently become commercially available, which will facilitate
the demonstration of their potential value as a diagnostic tool in
specimens of patients with cardiovascular disease (Table 1). Together with expression levels of MGP, the activity-status of the
protein may help to understand the precise function of MGP in
the local inhibition of vascular calcification.
Circulating MGP
MGP can also be detected in the circulation with ELISA-based
techniques. The use of a circulating biomarker for CVD and/or
vascular calcification is an attractive possibility. Its value in the
diagnostic area might be the pre-screening of patients before
subjecting them to electron beam or multislice CT scanning.
This technique is widely used to screen patients for coronary calcifications (98–100) but has the disadvantages of being expensive and posing an increased cancer risk due to the radiation load
(101). The latter is especially important for regular follow-up
during treatment. The crusade for finding biomarkers representing or predicting vascular disease has led to the development of
ELISA’s measuring proteins involved in the calcification process
(20, 102–104). Of these proteins, only the function of MGP can
be modulated, by either vitamin K or vitamin K-antagonists.
Circulating levels of MGP will depend on the rate of MGP synthesis in vascular tissue, its secretion from VSMCs and subsequent binding of MGP to calcified areas that may be present
within the arterial wall. Currently it is not known in which forms
MGP circulates. Mature MGP is highly insoluble and it is not
fully understood how and whether it circulates as a free protein or
associated with a carrier. Full-length MGP has been purified
from the plasma of rats as a complex including calcium, phosphate, carboxylated MGP and fetuin (105). On the other hand,
uncarboxylated MGP was purified from the plasma as mature 11
kD protein (106). Additionally, it is likely that also a substantial
fraction of plasma MGP occurs as fragments.
MGP can undergo two posttranslational modifications: the
aminoacid sequence 3–15 with three serine (ser) residues which
can be phosphorylated, and aminoacid sequence 35–53 containing four glutamate residues (glu) which can be carboxylated into
γ-carboxylglutamate (gla) (Fig. 1 and Table 1). These modifications result in several possible MGP conformations which can be
set free in the circulation (Table 2). In the literature three assays
for circulating MGP have been described. All three tests described are single antibody assays that do not discriminate between the full length molecule and fragments thereof (107–109).
The first published assay is a single antibody ELISA using a
monoclonal antibody specific for the non-phosphorylated N-terminal MGP aminoacid sequence 3–15 (107, 108). This assay
only measures non-phosphorylated MGP (dpMGP), and does
not discriminate between cMGP and ucMGP. It has been reported the the dpMGP fraction is only a minority of the total
MGP produced (4). Using a proteomics approach, Wajih et al.
proposed that the phosphorylated fraction is secreted into the
extra-cellular environment, whereas the non-phosphorylated
form is only secreted as matrix vesicles or apopotic bodies (7).
Thus, non-phosphorylated MGP may predict the VSMC stress
locally. Increased levels of serum MGP were measured in patients with severe atherosclerosis and with type I diabetes mellitus using this assay (107). The same assay was used in collaboration with Jono et al. (110). In this study the severity of coronary
artery calcification (CAC) was measured with electron beam CT
(EBCT) in subjects with suspected coronary artery disease, and
MGP was measured in serum samples from these subjects. The
serum levels of MGP were significantly lower in subjects with
CAC compared to those without CAC. Moreover, serum MGP
levels were inversely correlated with the severity of CAC. This is
consistent with data obtained in experimental animals in which
significantly lower MGP levels were measured in animals with
massive arterial calcifications (20, 47). An explanation for this
can be the phenotypically change of VSMCs into osteoblast-like
cells as response to the calcification, and subsequent down-regulation of MGP synthesis.
The second MGP assay, which is not commercially available,
is a radioimmunoassay using polyclonal antibodies directed
against MGP purified from human bone (109). With this assay it
is not possible to discriminate between the different MGP conformations. Using this assay, O’Donnell et al. found a significant
positive correlation between circulating MGP levels and coronary heart disease risk factors (Framingham CHD risk score) in
both men and women. Especially the traditional lipid-risk factors
correlated significantly with serum MGP levels. However, no
significant correlation was found between MGP levels and CAC.
Recently, a competitive ELISA using monoclonal antibodies
directed against the non-carboxylated MGP sequence 35–53 to
measure circulating ucMGP levels was described (106, 111).
Since this is also a single antibody assay, it does not discriminate
between 1. full length MGP or fragments or 2. phosphorylated
MGP (pMGP) and dpMGP. The assay was validated in a wide
range of patient populations prone to develop arterial calcification, including patients with atherosclerosis and renal dysfunction (106). All patient groups had significantly lower
ucMGP values than healthy subjects of comparable age. This
assay was particularly successful in identifying patients with
end-stage renal disease (ESRD) and calciphylaxis, a condition
characterized by extensive calcification of cutaneous arterioles.
MGP levels in these patients were almost without exceptions
below the normal range (106). Additionally, it was demonstrated
that circulating ucMGP levels were inversely associated with the
aortic augmentation index (111). Moreover, in a well characterized cohort of ESRD patients we found an inverse correlation between circulating MGP levels and CAC scores measured by
MSCT (E. C. M. Cranenburg et al., submitted for publication).
These results could indicate that low MGP levels may be a
marker of active calcification. The low MGP levels in these patient populations could be explained by the accumulation of
ucMGP at sites of arterial calcification (14, 56, 57), suggesting
that ucMGP is not set free into the circulation. An additional explanation for the low ucMGP levels could be that the majority of
ucMGP is in the p-ucMGP form and that phosphorylation alone
is sufficient for the binding of MGP to vascular calcifications
(Fig. 2C). Indeed, previously we found no correlation between
the dpMGP and ucMGP measurements in patients (R2 0.008, p =
600
0.385) (106). To interpret these data, one could speculate that
MGP is processed in a phosphorylated form, and that also the
vitamin K-metabolism is impaired (as deduced from the ucMGP
levels).
All MGP assays described above have in common that – if
analysed on a group level – patients with CVD can be identified.
However, further research is necessary to establish the value of
this assay.
Ongoing research and future perspectives of MGP as
biomarker
We aimed to develop an MGP ELISA to follow-up vitamin
K-status after intervention (e.g. supplementation with vitamin
K, or treatment with coumarin derivatives). Additionally, we intended to measure MGP species which are most readily set free
in the circulation, independent of the presence of vascular calcification. It can be hypothesized that all forms of MGP containing the very negatively charged carboxylated or phosphorylated
domains have a high affinity for precipitated calcium and will
accumulate in and around calcified lesions in the vasculature
(Fig. 2). As we found that in patients prone for vascular disease/
calcification both the pMGP and ucMGP where decreased (see
above), we hypothesise that only the non-phosphorylated, noncarboxylated MGP conformation will be easily set free in the circulation, independent of the vascular tissue calcium content,
since this conformation has the lowest affinity for calcium (Fig.
2). Therefore, we developed a sandwich ELISA measuring nonphosphorylated, non-carboxylated MGP (dp-ucMGP).
We first tested the dp-ucMGP assay in a healthy control
population, divided into groups aged 20 to 45 years and 50 years
and older. The dp-ucMGP fraction was indeed measurable in
plasma of these apparently healthy subjects (data not shown).
The presence of inactive MGP in healthy subjects is consistent
with data on osteocalcin, another vitamin K-dependent protein
produced exclusively in bone (112, 113). It is generally accepted
that the vitamin K-status is sufficient for normal haemostasis,
but that extra-hepatic tissues such as bone and vascular are marginal in vitamin K (93, 112, 114). Secondly, we measured dpucMGP in two groups with extremes in vitamin K status: patients
receiving vitamin K-antagonists (coumarin derivatives) as oral
anticoagulant therapy and healthy volunteers receiving supplements with vitamin K (Fig. 3). Significantly increased circulating dp-ucMGP levels were found in patients receiving vitamin
K-antagonists, whereas low levels of dp-ucMGP were present in
healthy volunteers on vitamin K-supplementation. When MGP
status was measured before and after a period of high vitamin K
intake it was found that the dp-ucMGP level even decreased
below the detection limit. These data indicate that this assay may
become a marker for vitamin K-status of the arterial vessel wall.
The dp-ucMGP assay is currently under validation, the details of
which will be published elsewhere.
Conclusions
Vascular calcification is a major determinant of cardiovascular
mortality and recent data demonstrate that one of the main calcification inhibitors in the vasculature is MGP. Although the vascular calcification is associated with poor cardiovascular out-
Figure 3: The dp-ucMGP assay is based on the sandwich ELISAprinciple. In brief, monoclonal anti-dpMGP was coated to the microtiter plate. After blocking, either sample (citrated plasma or EDTA) or
standard was incubated. The standard peptide was synthetic MGP, based
on the non-phosphorylated 3–15aa sequence and the non-carboxylated
35–54aa sequence, linked with a hydrophilic spacer (Pepscan, Lelystad,
the Netherlands). After incubation and washing, the standard or sample
was detected using a biotinylated monoclonal ucMGP antibody. Plasma
dp-ucMGP levels in the reference subjects, patients on oral anticoagulant
treatment and subjects receiving vitamin K supplements are depicted.
The reference group was divided into two groups: age less than 40
years, and age 50 or more. Mean ± SD ucMGP values of young healthy
controls, elderly healthy controls, patients on coumarins and subjects receiving vitamin K-supplements were 389 ± 182, 312 ± 109, 172 ± 82,
and 140 ± 55 nM, respectively (depicted as horizontal bars).
come, Huang et al. showed in post-mortem coronary arteries that
massive calcification is not related to plaque stress (115). Inspection of human atherosclerotic lesions revealed an association between plaque rupture and punctated intimal calcium deposition, possibly originated from small cell membrane fragments (116). Thus, the exact role of calcification in unstable
plaque development is still unknown. The value of the calcification score (assessed by multislice CT scan) is therefore still
under debate. Although calcification is regarded as an actively
regulated process, it is likely that the massive arterial calcifications represent an end-stage process. The measurement of
biomarkers, which can reflect the early signs of vascular disease
could be of great importance. Both cardiovascular calcification
and MGP activity are directly correlated with vitamin K2 intake
(6, 47, 81). Remarkably, most subjects in the healthy population
are not optimally protected against calcification, since part of
their MGP occurs in an uncarboxylated, inactive form (93, 106).
The presence of MGP can now be detected accurately, and could
be regarded as an independent risk factor for CVD; fortunately,
this risk factor can be annihilated by increased vitamin K intake.
Experiments in rats suggest this possibility by regression of calcification (47), but presently no data in humans are available to
suggest that high vitamin K intake may contribute to regression
of vascular calcification in CVD patients. Accumulating data
suggest, however, that a high vitamin K2 intake may be an effective interventional strategy to decrease the calcification risk in
the general population.
601
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification
References
1. Price PA, et al. Matrix Gla protein, a new gammacarboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983; 117: 765–771.
2. Shanahan CM, et al. High expression of genes for
calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994; 93: 2393–2402.
3. Fraser JD, Price PA. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible
functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J Biol Chem
1988; 263: 11033–11036.
4. Price PA, et al. Conserved phosphorylation of serines in the Ser-X-Glu/Ser(P) sequences of the vitamin
K-dependent matrix Gla protein from shark, lamb, rat,
cow, and human. Protein Sci 1994; 3: 822–308.
5. Berkner KL, Runge KW. The physiology of vitamin
K nutriture and vitamin K-dependent protein function
in atherosclerosis. J Thromb Haemost 2004; 2:
2118–2132.
6. Geleijnse JM, et al. Dietary intake of menaquinone
is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr 2004; 134:
3100–3105.
7. Wajih N, et al. Processing and transport of matrix
gamma-carboxyglutamic acid protein and bone morphogenetic protein-2 in cultured human vascular
smooth muscle cells: evidence for an uptake mechanism for serum fetuin. J Biol Chem 2004; 279:
43052–43060.
8. Adams SL, et al. Integration of signaling pathways
regulating chondrocyte differentiation during endochondral bone formation. J Cell Physiol 2007; 213:
635–641.
9. Cancela ML, Price PA. Retinoic acid induces matrix Gla protein gene expression in human cells. Endocrinology 1992; 130: 102–108.
10. Rannels SR, et al. Matrix Gla protein mRNA expression in cultured type II pneumocytes. Am J Physiol
1993; 265: 270–278.
11. Farzaneh-Far A, et al. Transcriptional regulation of
matrix gla protein. Z Kardiol 2001; 90: 38–42.
12. Kirfel J, et al. Identification of a novel negative retinoic acid responsive element in the promoter of the
human matrix Gla protein gene. Proc Natl Acad Sci
USA 1997; 94: 2227–2232.
13. Jono S, et al. 1,25-Dihydroxyvitamin D3 increases
in vitro vascular calcification by modulating secretion
of endogenous parathyroid hormone-related peptide.
Circulation 1998; 98: 1302–1306.
14. Price PA, et al. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000; 20: 317–27.
15. Kerr DN. Hypercalcemia and metastatic calcification. Cardiovasc Res 1997; 36: 293–297.
16. Price PA, et al. Excessive mineralization with
growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci USA 1982; 79: 7734–7738.
17. Howe AM, Webster WS. The warfarin embryopathy: a rat model showing maxillonasal hypoplasia
and other skeletal disturbances. Teratology 1992; 46:
379–390.
18. Hale JE, et al. The identification of matrix Gla protein in cartilage. J Biol Chem 1988; 263: 5820–5824.
19. Luo G, et al. Spontaneous calcification of arteries
and cartilage in mice lacking matrix GLA protein. Nature 1997; 386: 78–81.
20. Price PA, et al. Warfarin causes rapid calcification
of the elastic lamellae in rat arteries and heart valves.
Arterioscler Thromb Vasc Biol 1998; 18: 1400–1407.
21. Steitz SA, et al. Smooth muscle cell phenotypic
transition associated with calcification: upregulation of
Cbfa1 and downregulation of smooth muscle lineage
markers. Circ Res 2001; 89: 1147–1154.
22. Wallin R, et al. Modulation of the binding of matrix
Gla protein (MGP) to bone morphogenetic protein-2
(BMP-2). Thromb Haemost 2000; 84: 1039–1044.
23. Zebboudj AF, et al. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol
Chem 2002; 277: 4388–4394.
24. Boström K, et al. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest
1993; 91: 1800–1809.
25. Bostrom K, et al. Matrix GLA protein modulates
differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 2001; 276:
14044–14052.
26. Shanahan CM, et al. Medial localization of mineralization-regulating proteins in association with
Monckeberg's sclerosis: evidence for smooth muscle
cell-mediated vascular calcification. Circulation 1999;
100: 2168–2176.
27. Nishimoto SK, Nishimoto M. Matrix Gla protein
C-terminal region binds to vitronectin. Co-localization
suggests binding occurs during tissue development.
Matrix Biol 2005; 24: 353–361.
28. Stehbens WE. The significance of programmed cell
death or apoptosis and matrix vesicles in atherogenesis.
Cell Mol Biol 2000; 46: 99–110.
29. Bennett MR, et al. Apoptosis of human vascular
smooth muscle cells derived from normal vessels and
coronary atherosclerotic plaques. J Clin Invest 1995;
95: 2266–2274.
30. Schoppet M, et al. Localization of osteoprotegerin,
tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB
ligand in Mönckeberg's sclerosis and atherosclerosis. J
Clin Endocrinol Metab 2004; 89: 4104–4112.
31. Perlman H, et al. Evidence for the rapid onset of
apoptosis in medial smooth muscle cells after balloon
injury. Circulation 1997; 95: 981–987.
32. Kim KM. Calcification of matrix vesicles in human
aortic valve and aortic media. Fed Proc 1976; 35:
156–162.
33. Hsu HH, Camacho NP. Isolation of calcifiable vesicles from human atherosclerotic aortas. Atherosclerosis 1999; 143: 353–362.
34. Reynolds JL, et al. Human vascular smooth muscle
cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004; 15: 2857–2867.
35. Murshed M, et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004; 165: 625–630.
36. Munroe PB, et al. Mutations in the gene encoding
the human matrix Gla protein cause Keutel syndrome.
Nat Genet 1999; 21: 142–144.
37. Hur DJ, et al. A novel MGP mutation in a consanguineous family: review of the clinical and molecular
characteristics of Keutel syndrome. Am J Med Genet A
2005; 135: 36–40.
38. Meier M, et al. Tracheobronchial stenosis in Keutel
syndrome. Eur Respir J 2001; 17: 566–569.
39. Zieman SJ, et al. Mechanisms, pathophysiology,
and therapy of arterial stiffness. Arterioscler Thromb
Vasc Biol 2005; 25: 932–943.
40. Doherty TM, et al. Calcification in atherosclerosis:
bone biology and chronic inflammation at the arterial
crossroads. Proc Natl Acad Sci USA 2003; 100:
11201–11206.
602
41. Rosenhek R, et al. Predictors of outcome in severe,
asymptomatic aortic stenosis. N Engl J Med 2000; 343:
611–617.
42. Blacher J, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease.
Hypertension 2001; 38: 938–942.
43. London GM, et al. Arterial media calcification in
end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;
18: 1731–1740.
44. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz
2001; 26: 245–251.
45. Essalihi R, et al. Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic
anhydrase. Circulation 2005; 112: 1628–1635.
46. Bas A, et al. Reversibility of calcitriol-induced
medial artery calcification in rats with intact renal
function. J Bone Miner Res 2006; 21: 484–490.
47. Schurgers LJ, et al. Regression of warfarin-induced
medial elastocalcinosis by high intake of vitamin K in
rats. Blood 2007; 109: 2823–2831.
48. Price PA, et al. Artery calcification in uremic rats is
increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006; 70:
1577–1583.
49. Raggi P, et al. Aggressive versus moderate lipidlowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with
EBT Scanning (BELLES). Circulation 2005; 112:
563–571.
50. Cowell SJ, et al. A randomized trial of intensive
lipid-lowering therapy in calcific aortic stenosis. N
Engl J Med 2005; 352: 2389–2397.
51. US Renal Data System. USRDS 1998 annual data
report. Bethesda: National Institute of Diabetes and
Kidney Diseases. 1999; 63–90.
52. US Renal Data System. USRDS 1998 annual data
report. Bethesda: National Institute of Diabetes and
Kidney Diseases. 1999; 79–90.
53. Raggi P, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol
2002; 39: 695–701.
54. Goodman WG, et al. Coronary-artery calcification
in young adults with end-stage renal disease who are
undergoing dialysis. N Engl J Med 2000; 342:
1478–1483.
55. Pilkey RM, et al. Subclinical vitamin K deficiency
in hemodialysis patients. Am J Kidney Dis 2007; 49:
432–439.
56. Sweatt A, et al. Matrix Gla protein (MGP) and bone
morphogenetic protein-2 in aortic calcified lesions of
aging rats. J Thromb Haemost 2003; 1: 178–185.
57. Schurgers LJ, et al. Novel conformation-specific
antibodies against matrix gamma-carboxyglutamic
acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler
Thromb Vasc Biol 2005; 25: 1629–1633.
58. Hall JG, et al. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68:
122–140.
59. Becker MH, et al. Chondrodysplasis punctata: is
maternal warfarin therapy a factor? Am J Dis Child
1975; 129: 356–359.
60. Shaul WL, et al. Chondrodysplasia punctata and
maternal warfarin use during pregnancy. Am J Dis
Child 1975; 129: 360–362.
61. Shaul WL, Hall JG. Multiple congenital anomalies
associated with oral anticoagulants. Am J Obstet Gynecol 1977; 127: 191–198.
62. Howe AM, et al. Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K. Am
J Med Genet 1995; 58: 238–244.
63. Pauli RM, et al. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy:
clues to the mechanism of teratogenicity of coumarin
derivatives. Am J Hum Genet 1987; 41: 566–583.
64. Keith DA, Gallop PM. Phenytoin, hemorrhage,
skeletal defects and vitamin K in the newborn. Med
Hypotheses 1979; 5: 1347–1351.
65. Menger H, et al. Vitamin K deficiency embryopathy: a phenocopy of the warfarin embryopathy due to
a disorder of embryonic vitamin K metabolism. Am J
Med Genet 1997; 72: 129–134.
66. Khau Van Kien P, et al. Vitamin K deficiency embryopathy. Am J Med Genet 1998; 79: 66–68.
67. Eash DD, et al. Cervical spine stenosis and possible
vitamin K deficiency embryopathy in an unusual case
of chondrodysplasia punctata and an updated classification system. Am J Med Genet A 2003; 122: 70–75.
68. Jaillet J, et al. Biliary lithiasis in early pregnancy
and abnormal development of facial and distal limb
bones (Binder syndrome): a possible role for vitamin K
deficiency. Birth Defects Res A Clin Mol Teratol 2005;
73: 188–193.
69. Brunetti-Pierri N, et al. Gray matter heterotopias
and brachytelephalangic chondrodysplasia punctata: A
complication of hyperemesis gravidarum induced vitamin K deficiency? Am J Med Genet A 2007; 143:
200–204.
70. Hirsh J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692–1711.
71. Vermeer C, Hamulyak K. Pathophysiology of vitamin K-deficiency and oral anticoagulants. Thromb
Haemost 1991; 66: 153–159.
72. Schurgers LJ, et al. Oral anticoagulant treatment:
friend or foe in cardiovascular disease? Blood 2004;
104: 3231–3232.
73. Koos R, et al. Relation of oral anticoagulation to
cardiac valvular and coronary calcium assessed by
multislice spiral computed tomography. Am J Cardiol
2005; 96: 747–749.
74. Tokita H, et al. Vitamin K2-induced antitumor effects via cell-cycle arrest and apoptosis in gastric
cancer cell lines. Int J Mol Med 2006; 17: 235–243.
75. Mizuta T, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in
patients with hepatocellular carcinoma after curative
treatment: a pilot study. Cancer 2006; 106: 867–872.
76. Koshihara Y, et al. Vitamin K2 (menatetrenone) inhibits prostaglandin synthesis in cultured human osteoblast-like periosteal cells by inhibiting prostaglandin H synthase activity. Biochem Pharmacol 1993; 46:
1355–1362.
77. Hara K, et al. The inhibitory effect of vitamin K2
(menatetrenone) on bone resorption may be related to
its side chain. Bone 1995; 16: 179–184.
78. Tabb MM, et al. Vitamin K2 regulation of bone
homeostasis is mediated by the steroid and xenobiotic
receptor SXR. J Biol Chem 2003; 278: 43919–43927.
79. Wallin R, et al. Effects of the blood coagulation vitamin K as an inhibitor of arterial calcification. Thromb
Res 2008; in press.
80. Braam LA, et al. Beneficial effects of vitamins D
and K on the elastic properties of the vessel wall in
postmenopausal women: a follow-up study. Thromb
Haemost 2004; 91: 373–380.
81. Spronk HM, et al. Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res 2003; 40:
531–537.
82. Thijssen HH, et al. Phylloquinone and menaquinone-4 distribution in rats: synthesis rather than uptake
determines menaquinone-4 organ concentrations. J
Nutr 1996; 126: 537–543.
83. Buitenhuis HC, et al. Comparison of the vitamins
K1, K2 and K3 as cofactors for the hepatic vitamin
K-dependent carboxylase. Biochim Biophys Acta
1990; 1034: 170–175.
84. Thijssen HH, et al. Menadione is a metabolite of
oral vitamin K. Br J Nutr 2006; 95: 260–266.
85. Brenner B, et al. A missense mutation in gammaglutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 1998; 92: 4554–4559.
86. Spronk HMH, et al. Novel mutation in the gammaglutamyl carboxylase gene resulting in congenital combined deficiency of all vitamin K-dependent blood coagulation factors. Blood 2000; 96: 3650–3652.
87. Vanakker OM, et al. Pseudoxanthoma elasticumlike phenotype with cutis laxa and multiple coagulation
factor deficiency represents a separate genetic entity. J
Invest Dermatol 2007; 127: 581–587.
88. Ringpfeil F, et al. Molecular genetics of pseudoxanthoma elasticum. Exp Dermatol 2001; 10: 221–228.
89. Li Q, et al. Pseudoxanthoma elasticum: reduced
gamma-glutamyl carboxylation of matrix gla protein in
a mouse model (Abcc6-/-). Biochem Biophys Res
Commun 2007; 364: 208–213.
90. Gheduzzi D, et al. Matrix Gla protein is involved in
elastic fiber calcification in the dermis of pseudoxanthoma elasticum patients. Lab Invest 2007; 87:
998–1008.
91. Stafford DW. The vitamin K cycle. J Thromb Haemost 2005; 3: 1873–1878.
92. Wallin R, et al. Matrix Gla protein synthesis and
gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells--a cell system
which resembles the system in bone cells. Thromb Haemost 1999; 82: 1764–1767.
93. Cranenburg EC, et al. Vitamin K: The coagulation
vitamin that became omnipotent. Thromb Haemost
2007; 98: 120–125.
94. Wang Y, et al. VKORC1 haplotypes are associated
with arterial vascular diseases (stroke, coronary heart
disease, and aortic dissection). Circulation 2006; 113:
1615–1621.
95. Mukai K, et al. Stopped-flow kinetic study of vitamin E regeneration reaction with biological hydroquinones (reduced forms of ubiquinone, vitamin K, and tocopherolquinone) in solution. J Biol Chem 1992; 267:
22277–22281.
96. Vervoort LM, et al. The potent antioxidant activity
of the vitamin K cycle in microsomal lipid peroxidation. Biochem Pharmacol 1997; 54: 871–876.
97. Dhore CR, et al. Differential expression of bone
matrix regulatory proteins in human atherosclerotic
plaques. Arterioscler Thromb Vasc Biol 2001; 21:
1998–2003.
98. Raggi P, James G. Coronary calcium screening and
coronary risk stratification. Curr Atheroscler Rep
2004; 6: 107–111.
99. Raggi P, et al. Prognostic value of coronary artery
calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004; 43: 1663–1669.
603
100. Sun Z, et al. Diagnostic value of 64-slice CT angiography in coronary artery disease: A systematic review. Eur J Radiol 2008; 67: 78–84
101. Brenner DJ, Hall EJ. Computed tomography--an
increasing source of radiation exposure. N Engl J Med
2007; 357: 2277–2284.
102. Ketteler M, et al. Association of low fetuin-A
(AHSG) concentrations in serum with cardiovascular
mortality in patients on dialysis: a cross-sectional
study. Lancet 2003; 361: 827–833.
103. Vik A, et al. Serum osteoprotegerin is inversely
associated with carotid plaque echogenicity in humans.
Atherosclerosis 2007; 191: 128–134.
104. Anand DV, et al. The relationship between plasma
osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am
Coll Cardiol 2006; 47: 1850–1857.
105. Price PA, et al. Discovery of a high molecular
weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum
of etidronate-treated rats. J Biol Chem 2002; 277:
3926–3934.
106. Cranenburg EC, et al. The circulating inactive
form of Matrix Gla Protein (ucMGP) as a biomarker for
cardiovascular calcification. J Vasc Res 2008; 45:
427–436.
107. Braam LA, et al. Assay for human matrix gla protein in serum: potential applications in the cardiovascular field. Arterioscler Thromb Vasc Biol 2000; 20:
1257–1261.
108. Schurgers LJ, et al. Characteristics and performance of an immunosorbent assay for human matrix Glaprotein. Clin Chim Acta 2005; 351: 131–138.
109. O'Donnell CJ, et al. Matrix Gla protein is associated with risk factors for atherosclerosis but not with
coronary artery calcification. Arterioscler Thromb
Vasc Biol 2006; 26: 2769–2774.
110. Jono S, et al. Matrix Gla protein is associated with
coronary artery calcification as assessed by electronbeam computed tomography. Thromb Haemost 2004;
91: 790–794.
111. Hermans MM, et al. Undercarboxylated matrix
GLA protein levels are decreased in dialysis patients
and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif
2007; 25: 395–401.
112. Vermeer C, et al. Beyond deficiency: potential
benefits of increased intakes of vitamin K for bone and
vascular health. Eur J Nutr 2004; 43: 325–335.
113. Shearer MMJ. Role of vitamin K and Gla proteins
in the pathophysiology of osteoporosis and vascular
calcification. Curr Opin Clin Nutr Metab Care 2000; 3:
433–438.
114. Borst P, et al. Does the absence of ABCC6 (Multidrug Resistance Protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery? Cell Cycle 2008; 7:
1575–1579.
115. Huang H, et al. The impact of calcification on the
biomechanical stability of atherosclerotic plaques. Circulation 2001; 103: 1051–1056.
116. Shanahan CM. Inflammation ushers in calcification: a cycle of damage and protection? Circulation
2007; 116: 2782–2785.
117. Hackeng TM, et al. Total chemical synthesis of
human matrix Gla protein. Protein Sci 2001; 10:
864–870.
New vitamin K-dependent proteins
Schurgers et al. Matrix Gla-protein and vascular calcification